Compare PEP & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEP | NVS |
|---|---|---|
| Founded | 1898 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | 75267 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.4B | 286.5B |
| IPO Year | 1996 | N/A |
| Metric | PEP | NVS |
|---|---|---|
| Price | $141.93 | $152.92 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 5 |
| Target Price | ★ $166.79 | $144.00 |
| AVG Volume (30 Days) | ★ 8.5M | 1.7M |
| Earning Date | 04-16-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.66% | 2.16% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $93,925,000,000.00 | N/A |
| Revenue This Year | $5.78 | $2.30 |
| Revenue Next Year | $3.20 | $5.27 |
| P/E Ratio | $83.55 | ★ $23.13 |
| Revenue Growth | ★ 2.25 | N/A |
| 52 Week Low | $127.60 | $112.34 |
| 52 Week High | $171.48 | $170.46 |
| Indicator | PEP | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 59.49 |
| Support Level | $139.01 | $149.49 |
| Resistance Level | $143.42 | $158.80 |
| Average True Range (ATR) | 2.85 | 2.19 |
| MACD | 0.18 | 0.45 |
| Stochastic Oscillator | 33.17 | 99.42 |
PepsiCo is a global leader in snacks and beverages, owning well-known household brands including Pepsi, Mountain Dew, Gatorade, Lay's, Cheetos, and Doritos, among others. The company dominates the global savory snacks market and also ranks as the second-largest beverage provider in the world (behind Coca-Cola) with diversified exposure to carbonated soft drinks, or CSD, as well as water, sports, and energy drink offerings. Convenience foods account for approximately 58% of its total revenue, with beverages making up the rest. Pepsi owns the bulk of its manufacturing and distribution capacity in the US, but uses bottlers overseas for beverages. International markets made up 41% of total sales and 46% of operating profits before corporate expenses in 2025.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.